Palifosfamide

Summary

Palifosfamide (CHEMBL889) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including sarcoma and small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 6
• Chemistry: 221.02 Da · C4H11Cl2N2O2P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL889
Name	Palifosfamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	100427
Molecular formula	C4H11Cl2N2O2P
Molecular weight	221.02
InChIKey	BKCJZNIZRWYHBN-UHFFFAOYSA-N

SMILES: C(CCl)NP(=O)(NCCCl)O

IUPAC name: bis(2-chloroethylamino)phosphinic acid

Also known as: Ifosfamide mustard, IPM, Isophosphamide mustard, NSC-297900, Palifosfamida, Palifosfamide, ZIO-201, Ifosphoramide mustard, SID147379, PALIFOSFAMIDE, ISOPHOSPHORAMIDE MUSTARD LYSINE SALT

Parent form; salt/anhydrous children: CHEMBL2219419

Patent coverage: 573 distinct patent families (1,313 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
sarcoma	3	MONDO:0005089	EFO:0000691
small cell lung carcinoma	3	MONDO:0008433	EFO:0000702
soft tissue sarcoma	3	MONDO:0018078	EFO:1001968
breast neoplasm	2	MONDO:0021100	MONDO:0007254
neoplasm	1	MONDO:0005070	EFO:0000616

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	3
PHASE2	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00439686	PHASE1/PHASE2	COMPLETED	Study of ZIO-201 in Advanced Sarcoma
NCT01703754	PHASE2	TERMINATED	Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
NCT01808534	PHASE2	TERMINATED	Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
NCT00421135	PHASE1	COMPLETED	A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
NCT00607711	PHASE1	SUSPENDED	Study of Oral Palifosfamide Tris in Solid Tumors
NCT05041699	PHASE1	COMPLETED	PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).